Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Stoke Therapeutics, Inc. - Common Stock (NQ:STOK)

18.21 +1.04 (+6.06%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,967,233
Open 17.23
Bid (Size) 17.50 (5)
Ask (Size) 18.32 (3)
Prev. Close 17.17
Today's Range 16.90 - 18.45
52wk Range 5.350 - 18.45
Shares Outstanding 44,188,534
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Where Stoke Therapeutics Stands With Analysts
 
Via Benzinga
Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire

Performance

YTD
+61.6%
+61.6%
1 Month
+37.7%
+37.7%
3 Month
+85.2%
+85.2%
6 Month
+87.5%
+87.5%
1 Year
+22.7%
+22.7%

More News

Read More
A Look Ahead: Stoke Therapeutics's Earnings Forecast
Via Benzinga
Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For August 12, 2025
Via Benzinga
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
From Biogen Inc.
Via GlobeNewswire
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
From Stoke Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
D.R. Horton, IQVIA Holdings, Northrop Grumman And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
This Verint Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
From Stoke Therapeutics, Inc.
Via Business Wire
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
From Biogen Inc.
Via GlobeNewswire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
STOKE THERAPEUTICS INC (NASDAQ:STOK) – A Biotech Stock with Strong Growth Signals
Via Chartmill
Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar
Via Investor's Business Daily
Topics Earnings
Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
Forecasting The Future: 7 Analyst Projections For Stoke Therapeutics
Via Benzinga
Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Announces CEO Transition
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics to Present at Upcoming Investor Conferences in March
From Stoke Therapeutics, Inc.
Via Business Wire
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal
Via Benzinga

Frequently Asked Questions

Is Stoke Therapeutics, Inc. - Common Stock publicly traded?
Yes, Stoke Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Stoke Therapeutics, Inc. - Common Stock trade on?
Stoke Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Stoke Therapeutics, Inc. - Common Stock?
The ticker symbol for Stoke Therapeutics, Inc. - Common Stock is STOK on the Nasdaq Stock Market
What is the current price of Stoke Therapeutics, Inc. - Common Stock?
The current price of Stoke Therapeutics, Inc. - Common Stock is 18.21
When was Stoke Therapeutics, Inc. - Common Stock last traded?
The last trade of Stoke Therapeutics, Inc. - Common Stock was at 08/15/25 04:00 PM ET
What is the market capitalization of Stoke Therapeutics, Inc. - Common Stock?
The market capitalization of Stoke Therapeutics, Inc. - Common Stock is 804.67M
How many shares of Stoke Therapeutics, Inc. - Common Stock are outstanding?
Stoke Therapeutics, Inc. - Common Stock has 805M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.